Skip to main content
Premium Trial:

Request an Annual Quote

DiscernDx Acquires Luminist Labs

NEW YORK — DiscernDx said on Wednesday that it has acquired Luminist Labs, a privately held developer of diagnostic technology for nonalcoholic steatohepatitis (NASH) and other liver diseases.

Terms of the deal were not disclosed.

Founded in 2017, Palo Alto, California-based DiscernDx is building a platform that combines individualized clinical and molecular data in order to help guide treatment decisions. The company said it will integrate Luminist's technology into its platform to enhance its application in NASH and other chronic metabolic diseases.

Luminist is based in Newark, California.

"Our platform measures and interprets the dynamic changes in our bodies to provide personalized health insights," DiscernDx Cofounder and CEO Bruce Wilcox said in a statement. “The application of our proprietary multiomics platform to the unique sample and dataset created by Luminist Labs is expected to result in novel non-invasive diagnostic and prognostic solutions for patients living with NASH."

In early 2018, DiscernDx acquired the assets of Applied Proteomics for $1.85 million, primarily to gain access to that company's mass spectrometry technology and workflows.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.